+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID03850418

Study of Azacitidine to Improve Donor Chimerism and Reduce Relapse in Adults with MDS or AML After Allogeneic Stem Cell Transplant

Led by Henry Ford Health System · Updated on 2026-02-24

43

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying azacitidine in patients with myeloid malignancies such as AML or MDS who have undergone allogeneic stem cell transplant. The study aims to see if azacitidine can be tolerated after transplant and help maintain or increase donor chimerism, potentially reducing relapse without increasing graft-versus-host disease GVHD. This is a phase 2 interventional trial sponsored by Henry Ford Health System. Participants will receive azacitidine at a dose of 32 mgm2 daily for 5 days every 28 days, for a minimum of 4 cycles if tolerated. The treatment is given after transplant once patients show a decrease in donor chimerism or low chimerism without relapse. The study monitors patients over at least one year. During the study, participants will be regularly evaluated for changes in donor chimerism levels, with the primary outcome being the rate of increase or stability of donor chimerism at one year. Safety and tolerability will also be assessed. Patients must meet specific health criteria and undergo laboratory monitoring to ensure kidney, liver function, and blood counts are adequate. The total study duration varies by treatment cycles and follow-up.

CONDITIONS

Brief Title

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Research Team

S

shatha farhan, MD

N

NALINI JANAKIRAMAN, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here